Valuation: Imeik Technology Development Co.,Ltd.

Market Cap 30.81B 4.56B 3.99B 3.69B 3.39B 6.41B 440B 6.52B 44.09B 17.26B 215B 17.12B 16.75B 741B P/E 2026 *
22.6x
P/E 2027 * 19.7x
Enterprise Value 28.59B 4.23B 3.7B 3.42B 3.14B 5.95B 408B 6.05B 40.9B 16.01B 199B 15.88B 15.54B 687B EV / Sales 2026 *
10.7x
EV / Sales 2027 * 8.97x
Free-Float
40.13%
Yield 2026 *
1.9%
Yield 2027 * 2.53%
Jun. 25 Chengdu lncTAC Biotechnology Co., Ltd. announced that it has received CNY 300 million in funding from Legend Capital Management Co., Ltd., Lapam Capital, Imeik Technology Development Co.,Ltd., Riverhead Capital Investment Management Co., Ltd., Zhejiang Huafang Asset Management Co., Ltd., Shanghai Pan-Lin Asset Management Co., Ltd. CI
Jun. 25 Chengdu Lingtaike Biotechnology Co., Ltd. announced that it has received funding from Shanghai Pan-Lin Asset Management Co., Ltd., Zhejiang Huafang Asset Management Co., Ltd., Imeik Technology Development Co.,Ltd., Riverhead Capital Investment Management Co., Ltd., Legend Capital Management Co., Ltd. CI
Apr. 22 Imeik Technology Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 22 Imeik Technology Development Q1 net profit down 32.8% Y/Y RE
Apr. 01 Nomura Starts Imeik Technology Development at Neutral With 123.90 Yuan Price Target MT
Mar. 19 Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Mar. 19 Imeik technology development's 2025 net profit down 34.1% y/y RE
Jan. 09 Imeik Technology Development Gets Approval for Botox Injection; Shares Up 3% MT
Nov. 14 Imeik Technology Development Co.,Ltd. Announces Directorate Appointments CI
Nov. 13 Imeik technology development's board elects chairwoman RE
25-10-28 Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-10-28 Imeik Technology Development Q3 net profit down 34.6% Y/Y RE
25-09-12 Imeik Technology Development Co.,Ltd. Approves Interim Cash Profit Distribution Plan to Be Implemented on A Shares for 2025, Payable on 26 September 2025 CI
1 day+1.67%
1 week+14.29%
Current month+17.24%
1 month+11.90%
3 months-10.76%
6 months-30.53%
Current year-27.86%
1 week 85.24
Extreme 85.24
102.7
1 month 83.36
Extreme 83.36
102.7
Current year 83.36
Extreme 83.36
158.8
1 year 83.36
Extreme 83.36
202.88
3 years 83.36
Extreme 83.36
352.42
5 years 83.36
Extreme 83.36
580.71
10 years 83.36
Extreme 83.36
603.17
Manager TitleAgeSince
Chief Executive Officer 52 2010-12-31
Director of Finance/CFO 48 2021-10-31
Corporate Secretary 58 2016-06-23
Director TitleAgeSince
Chairman 63 2010-12-31
Director/Board Member 52 2010-12-31
Director/Board Member 62 2010-12-31
Date Insider Type Main position Quantity % Market Cap.
12/19/23 Buy

Chairman

9,000 0.0042%
12/6/23 Buy

Chairman

50,000 0.0231%
11/23/23 Buy

Chairman

70,000 0.0324%
Change 5-day change 1-year change 3-year change Capi.($)
+1.67%+14.29%-42.45%-67.47% 4.47B
-0.23%-3.23%-18.04%+8.37% 123B
-1.13%-0.18%+1.16%-4.73% 13.03B
-0.87%+1.79%+59.12%+100.88% 9.21B
+0.98%+0.85%+6.39%+47.04% 2.7B
+0.80%-6.61%-22.01%-30.66% 1.62B
+3.55%+3.10%-9.81%-18.90% 1.6B
-0.85%+4.23%+2.09%-58.82% 1.56B
+5.28%+2.92%-58.00%-83.40% 1.46B
Average +1.02%+1.89%-9.06%-11.97% 17.58B
Weighted average by Cap. -0.17%-1.62%-12.37%+9.01%

Financials

2026 *2027 *
Net sales 2.66B 394M 345M 319M 293M 554M 37.99B 563M 3.81B 1.49B 18.56B 1.48B 1.45B 64.02B 3.1B 459M 401M 371M 341M 645M 44.25B 656M 4.44B 1.74B 21.62B 1.72B 1.69B 74.57B
Net income 1.37B 202M 177M 164M 150M 284M 19.51B 289M 1.96B 766M 9.53B 760M 743M 32.88B 1.57B 232M 203M 188M 172M 326M 22.37B 332M 2.24B 878M 10.93B 871M 852M 37.7B
Net Debt -2.23B -330M -288M -267M -245M -464M -31.81B -472M -3.19B -1.25B -15.54B -1.24B -1.21B -53.6B -2.99B -442M -386M -357M -328M -621M -42.61B -632M -4.27B -1.67B -20.82B -1.66B -1.62B -71.81B
Logo Imeik Technology Development Co.,Ltd.
Imeik Technology Development Co Ltd is a China-based company mainly engaged in the research and development, production and sales of biomedical materials. The Company focuses on the development and transformation of biomedical materials, and is committed to the development of biomedicine such as recombinant proteins and peptides. The Company has realized the industrialization of injection-type sodium hyaluronate series products and polydioxanone facial implants, and has established a product technology transformation platform for biomedical materials such as medical chitosan and polylactic acid. The Company's self-developed products are mainly aimed at the repair of fold skin on the face and neck. The clinical applications of its products cover medical cosmetology, surgical repair, and treatment of metabolic diseases. The Company mainly conducts its businesses in the China market.
Employees
1,458
Date Price Change Volume
26-07-20 CN¥102.23 +1.67% 9,286,447
26-07-17 CN¥100.55 +3.09% 10,310,482
26-07-16 CN¥97.54 +3.39% 10,410,943
26-07-15 CN¥94.34 +9.11% 9,145,665
26-07-14 CN¥86.46 -0.52% 2,965,748
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
102.23CNY
Average target price
147.32CNY
Spread / Average Target
+44.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 300896 Stock